Meriva® ||| S:0 E:7 ||| NNP
,  ||| S:7 E:9 ||| ,
a  ||| S:9 E:11 ||| DT
lecithinized  ||| S:11 E:24 ||| JJ
curcumin  ||| S:24 E:33 ||| JJ
delivery  ||| S:33 E:42 ||| NN
system ||| S:42 E:48 ||| NN
,  ||| S:48 E:50 ||| ,
in  ||| S:50 E:53 ||| IN
diabetic  ||| S:53 E:62 ||| JJ
microangiopathy  ||| S:62 E:78 ||| NN
and  ||| S:78 E:82 ||| CC
retinopathy  ||| S:82 E:94 ||| NN
In  ||| S:94 E:97 ||| IN
the  ||| S:97 E:101 ||| DT
present  ||| S:101 E:109 ||| JJ
study ||| S:109 E:114 ||| NN
,  ||| S:114 E:116 ||| ,
the  ||| S:116 E:120 ||| DT
improvement  ||| S:120 E:132 ||| NN
of  ||| S:132 E:135 ||| IN
diabetic  ||| S:135 E:144 ||| JJ
microangiopathy  ||| S:144 E:160 ||| NN
and  ||| S:160 E:164 ||| CC
retinopathy  ||| S:164 E:176 ||| NNS
was  ||| S:176 E:180 ||| VBD
evaluated  ||| S:180 E:190 ||| VBN
in  ||| S:190 E:193 ||| IN
38  ||| S:193 E:196 ||| CD
diabetic  ||| S:196 E:205 ||| CD
patients  ||| S:205 E:214 ||| NNS
treated  ||| S:214 E:222 ||| VBN
with  ||| S:222 E:227 ||| IN
a  ||| S:227 E:229 ||| DT
novel  ||| S:229 E:235 ||| NN
curcumin  ||| S:235 E:244 ||| VBZ
phospholipids  ||| S:244 E:258 ||| JJ
delivery  ||| S:258 E:267 ||| NN
form  ||| S:267 E:272 ||| NN
( ||| S:272 E:273 ||| -LRB-
Meriva® ||| S:273 E:280 ||| NNP
) ||| S:280 E:281 ||| -RRB-
.  ||| S:281 E:283 ||| .
Diabetes  ||| S:283 E:292 ||| NNP
was  ||| S:292 E:296 ||| VBD
diagnosed  ||| S:296 E:306 ||| VBN
at  ||| S:306 E:309 ||| IN
least  ||| S:309 E:315 ||| JJS
5  ||| S:315 E:317 ||| CD
years  ||| S:317 E:323 ||| NNS
before  ||| S:323 E:330 ||| IN
inclusion  ||| S:330 E:340 ||| NN
and  ||| S:340 E:344 ||| CC
all  ||| S:344 E:348 ||| DT
patients  ||| S:348 E:357 ||| NNS
had  ||| S:357 E:361 ||| VBD
signs  ||| S:361 E:367 ||| NNS
of  ||| S:367 E:370 ||| IN
retinal  ||| S:370 E:378 ||| JJ
oedema  ||| S:378 E:385 ||| NN
and  ||| S:385 E:389 ||| CC
of  ||| S:389 E:392 ||| IN
peripheral  ||| S:392 E:403 ||| JJ
microangiopathy ||| S:403 E:418 ||| NN
.  ||| S:418 E:420 ||| .
Meriva®  ||| S:420 E:428 ||| NNP
was  ||| S:428 E:432 ||| VBD
administered  ||| S:432 E:445 ||| VBN
at  ||| S:445 E:448 ||| IN
the  ||| S:448 E:452 ||| DT
dosage  ||| S:452 E:459 ||| NN
of  ||| S:459 E:462 ||| IN
2  ||| S:462 E:464 ||| CD
tablets ||| S:464 E:471 ||| CD
/ ||| S:471 E:472 ||| CD
day  ||| S:472 E:476 ||| NN
( ||| S:476 E:477 ||| -LRB-
each  ||| S:477 E:482 ||| DT
tablet  ||| S:482 E:489 ||| NN
containing  ||| S:489 E:500 ||| VBG
500  ||| S:500 E:504 ||| CD
mg  ||| S:504 E:507 ||| CD
Meriva®  ||| S:507 E:515 ||| CD
corresponding  ||| S:515 E:529 ||| JJ
to  ||| S:529 E:532 ||| TO
100  ||| S:532 E:536 ||| CD
mg  ||| S:536 E:539 ||| CD
curcumin ||| S:539 E:547 ||| CD
)  ||| S:547 E:549 ||| -RRB-
for  ||| S:549 E:553 ||| IN
a  ||| S:553 E:555 ||| DT
period  ||| S:555 E:562 ||| NN
of  ||| S:562 E:565 ||| IN
at  ||| S:565 E:568 ||| IN
least  ||| S:568 E:574 ||| JJS
4  ||| S:574 E:576 ||| CD
weeks  ||| S:576 E:582 ||| NNS
in  ||| S:582 E:585 ||| IN
addition  ||| S:585 E:594 ||| NN
to  ||| S:594 E:597 ||| TO
the  ||| S:597 E:601 ||| DT
standard  ||| S:601 E:610 ||| JJ
management  ||| S:610 E:621 ||| NN
plan ||| S:621 E:625 ||| NN
,  ||| S:625 E:627 ||| ,
while  ||| S:627 E:633 ||| IN
a  ||| S:633 E:635 ||| DT
comparable  ||| S:635 E:646 ||| JJ
group  ||| S:646 E:652 ||| NN
of  ||| S:652 E:655 ||| IN
subjects  ||| S:655 E:664 ||| NNS
( ||| S:664 E:665 ||| -LRB-
n  ||| S:665 E:667 ||| CD
=  ||| S:667 E:669 ||| SYM
39 ||| S:669 E:671 ||| CD
)  ||| S:671 E:673 ||| -RRB-
followed  ||| S:673 E:682 ||| VBD
the  ||| S:682 E:686 ||| DT
standard  ||| S:686 E:695 ||| JJ
management  ||| S:695 E:706 ||| NN
plan  ||| S:706 E:711 ||| NN
alone ||| S:711 E:716 ||| RB
.  ||| S:716 E:718 ||| .
All  ||| S:718 E:722 ||| DT
subjects  ||| S:722 E:731 ||| NNS
( ||| S:731 E:732 ||| -LRB-
treatment  ||| S:732 E:742 ||| NN
and  ||| S:742 E:746 ||| CC
controls ||| S:746 E:754 ||| NNS
)  ||| S:754 E:756 ||| -RRB-
completed  ||| S:756 E:766 ||| VBD
the  ||| S:766 E:770 ||| DT
follow-up  ||| S:770 E:780 ||| JJ
period ||| S:780 E:786 ||| NN
,  ||| S:786 E:788 ||| ,
there  ||| S:788 E:794 ||| EX
were  ||| S:794 E:799 ||| VBD
no  ||| S:799 E:802 ||| DT
dropouts  ||| S:802 E:811 ||| NNS
and  ||| S:811 E:815 ||| CC
Meriva®  ||| S:815 E:823 ||| NNP
showed  ||| S:823 E:830 ||| VBD
an  ||| S:830 E:833 ||| DT
optimal  ||| S:833 E:841 ||| JJ
tolerability ||| S:841 E:853 ||| NN
.  ||| S:853 E:855 ||| .
At  ||| S:855 E:858 ||| IN
4  ||| S:858 E:860 ||| CD
weeks ||| S:860 E:865 ||| NNS
,  ||| S:865 E:867 ||| ,
microcirculatory  ||| S:867 E:884 ||| NN
and  ||| S:884 E:888 ||| CC
clinical  ||| S:888 E:897 ||| JJ
evaluations  ||| S:897 E:909 ||| NNS
indicated  ||| S:909 E:919 ||| VBD
an  ||| S:919 E:922 ||| DT
improvement  ||| S:922 E:934 ||| NN
of  ||| S:934 E:937 ||| IN
microangiopathy ||| S:937 E:952 ||| NN
.  ||| S:952 E:954 ||| .
In  ||| S:954 E:957 ||| IN
terms  ||| S:957 E:963 ||| NNS
of  ||| S:963 E:966 ||| IN
peripheral  ||| S:966 E:977 ||| JJ
microangiopathy ||| S:977 E:992 ||| NN
,  ||| S:992 E:994 ||| ,
in  ||| S:994 E:997 ||| IN
the  ||| S:997 E:1001 ||| DT
Meriva®  ||| S:1001 E:1009 ||| JJ
group ||| S:1009 E:1014 ||| NN
,  ||| S:1014 E:1016 ||| ,
there  ||| S:1016 E:1022 ||| EX
was  ||| S:1022 E:1026 ||| VBD
a  ||| S:1026 E:1028 ||| DT
significant  ||| S:1028 E:1040 ||| JJ
improvement  ||| S:1040 E:1052 ||| NN
in  ||| S:1052 E:1055 ||| IN
the  ||| S:1055 E:1059 ||| DT
venoarteriolar  ||| S:1059 E:1074 ||| JJ
response  ||| S:1074 E:1083 ||| NN
( ||| S:1083 E:1084 ||| -LRB-
p  ||| S:1084 E:1085 ||| CD
< ||| S:1085 E:1086 ||| SYM
0.05 ||| S:1086 E:1090 ||| CD
)  ||| S:1090 E:1092 ||| -RRB-
and  ||| S:1092 E:1096 ||| CC
a  ||| S:1096 E:1098 ||| DT
decrease  ||| S:1098 E:1107 ||| NN
in  ||| S:1107 E:1110 ||| IN
the  ||| S:1110 E:1114 ||| DT
score  ||| S:1114 E:1120 ||| NN
of  ||| S:1120 E:1123 ||| IN
peripheral  ||| S:1123 E:1134 ||| JJ
oedema  ||| S:1134 E:1141 ||| NNS
( ||| S:1141 E:1142 ||| -LRB-
p  ||| S:1142 E:1143 ||| CD
< ||| S:1143 E:1144 ||| SYM
0.05 ||| S:1144 E:1148 ||| CD
) ||| S:1148 E:1149 ||| -RRB-
,  ||| S:1149 E:1151 ||| ,
a  ||| S:1151 E:1153 ||| DT
sign  ||| S:1153 E:1158 ||| NN
typically  ||| S:1158 E:1168 ||| RB
associated  ||| S:1168 E:1179 ||| VBN
with  ||| S:1179 E:1184 ||| IN
the  ||| S:1184 E:1188 ||| DT
failure  ||| S:1188 E:1196 ||| NN
of  ||| S:1196 E:1199 ||| IN
the  ||| S:1199 E:1203 ||| DT
venoarteriolar  ||| S:1203 E:1218 ||| JJ
response ||| S:1218 E:1226 ||| NN
.  ||| S:1226 E:1228 ||| .
At  ||| S:1228 E:1231 ||| IN
the  ||| S:1231 E:1235 ||| DT
retinal  ||| S:1235 E:1243 ||| JJ
level ||| S:1243 E:1248 ||| NN
,  ||| S:1248 E:1250 ||| ,
high-resolution ||| S:1250 E:1265 ||| NNP
,  ||| S:1265 E:1267 ||| ,
duplex  ||| S:1267 E:1274 ||| JJ
scanning ||| S:1274 E:1282 ||| NN
,  ||| S:1282 E:1284 ||| ,
used  ||| S:1284 E:1289 ||| VBN
to  ||| S:1289 E:1292 ||| TO
measure  ||| S:1292 E:1300 ||| VB
retinal  ||| S:1300 E:1308 ||| JJ
flow ||| S:1308 E:1312 ||| NN
,  ||| S:1312 E:1314 ||| ,
showed  ||| S:1314 E:1321 ||| VBD
improvements  ||| S:1321 E:1334 ||| NNS
in  ||| S:1334 E:1337 ||| IN
the  ||| S:1337 E:1341 ||| DT
Meriva®  ||| S:1341 E:1349 ||| NN
treated  ||| S:1349 E:1357 ||| VBN
patients ||| S:1357 E:1365 ||| NNS
.  ||| S:1365 E:1367 ||| .
The  ||| S:1367 E:1371 ||| DT
evaluation  ||| S:1371 E:1382 ||| NN
of  ||| S:1382 E:1385 ||| IN
retinal  ||| S:1385 E:1393 ||| JJ
oedema  ||| S:1393 E:1400 ||| NNS
( ||| S:1400 E:1401 ||| -LRB-
Steigerwalt ||| S:1401 E:1412 ||| NNP
's  ||| S:1412 E:1415 ||| POS
scale ||| S:1415 E:1420 ||| NN
)  ||| S:1420 E:1422 ||| -RRB-
showed  ||| S:1422 E:1429 ||| VBD
an  ||| S:1429 E:1432 ||| DT
improvement  ||| S:1432 E:1444 ||| NN
associated  ||| S:1444 E:1455 ||| VBN
with  ||| S:1455 E:1460 ||| IN
improved  ||| S:1460 E:1469 ||| JJ
visual  ||| S:1469 E:1476 ||| JJ
acuity  ||| S:1476 E:1483 ||| NNS
( ||| S:1483 E:1484 ||| -LRB-
Snellen  ||| S:1484 E:1492 ||| NNP
scale ||| S:1492 E:1497 ||| NN
) ||| S:1497 E:1498 ||| -RRB-
.  ||| S:1498 E:1500 ||| .
There  ||| S:1500 E:1506 ||| EX
were  ||| S:1506 E:1511 ||| VBD
no  ||| S:1511 E:1514 ||| DT
clinical  ||| S:1514 E:1523 ||| JJ
or  ||| S:1523 E:1526 ||| CC
microcirculatory  ||| S:1526 E:1543 ||| JJ
effects  ||| S:1543 E:1551 ||| NNS
in  ||| S:1551 E:1554 ||| IN
controls ||| S:1554 E:1562 ||| NNS
.  ||| S:1562 E:1564 ||| .
These  ||| S:1564 E:1570 ||| DT
preliminary  ||| S:1570 E:1582 ||| JJ
observations ||| S:1582 E:1594 ||| NNS
,  ||| S:1594 E:1596 ||| ,
indicate  ||| S:1596 E:1605 ||| VBP
the  ||| S:1605 E:1609 ||| DT
value  ||| S:1609 E:1615 ||| NN
of  ||| S:1615 E:1618 ||| IN
curcumin ||| S:1618 E:1626 ||| NN
,  ||| S:1626 E:1628 ||| ,
when  ||| S:1628 E:1633 ||| WRB
administered  ||| S:1633 E:1646 ||| VBN
in  ||| S:1646 E:1649 ||| IN
a  ||| S:1649 E:1651 ||| DT
bioavailable  ||| S:1651 E:1664 ||| JJ
form  ||| S:1664 E:1669 ||| NN
as  ||| S:1669 E:1672 ||| IN
with  ||| S:1672 E:1677 ||| IN
Meriva® ||| S:1677 E:1684 ||| NNP
,  ||| S:1684 E:1686 ||| ,
in  ||| S:1686 E:1689 ||| IN
the  ||| S:1689 E:1693 ||| DT
management  ||| S:1693 E:1704 ||| NN
of  ||| S:1704 E:1707 ||| IN
diabetic  ||| S:1707 E:1716 ||| JJ
microangiopathy  ||| S:1716 E:1732 ||| NN
and  ||| S:1732 E:1736 ||| CC
retinopathy ||| S:1736 E:1747 ||| NN
.  ||| S:1747 E:1749 ||| .
